Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091470 | 0.85 | HPGD (0.73) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL3484950 | 0.84 | HPGD (0.68) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL8388592 | 0.81 | MEN1 (0.67) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL15113297 | 0.80 | MEN1 (0.67) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL4897413 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTHPGDPOLB | |
| SCHEMBL134430 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTHPGDPOLB | |
| SCHEMBL12534318 | 0.79 | HPGD (0.74) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL3279205 | 0.79 | HPGD (0.74) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL1090961 | 0.79 | MEN1 (0.64) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL1090261 | 0.79 | HPGD (0.77) | MEN1KMT2AMAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | MEN1 3385/4885KMT2A 2348/4885MAPT 2165/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | MEN1 3385/4885KMT2A 2348/4885MAPT 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.